Amendments to the Claims:

This listing of the claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) Process for generating a metal complexed agent, comprising:

~~-~~contacting ~~(I)~~ a solid phase bound organic conjugate represented by ~~the~~ formula (I) with $[M(H_20)_3(CO)_3]^{n+}$,



(I)

wherein:

the sphere is ~~the~~ a solid phase support;

C is a methylene group ~~that may be substituted by one or two groups~~;

R_4 and R_5, ~~which can be in particular~~ are independently selected from the group consisting of H, aliphatic substituents, ~~or~~ aromatic substituents, ~~or~~ RO, RS ~~or~~ and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond ~~that may or may not be present, that is coupled to the solid support and has activating properties towards nucleophilic attack to the C group and is preferably a phenyl, alkyl, allyl or aryl~~; and

each of R_1 and R_2 ~~are the same or different and are~~ is independently a metal coordinating group, ~~or~~ a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group ~~which solid phase bound organic conjugate is optionally~~ derivatized ~~at one or both of R_1 and R_2~~ with a biologically active molecule, ~~with (II) $[M(H_20)_3(CO)_3]^{n+}$~~,

wherein M is selected from the group consisting of technetium (Tc), rhenium (Re), rhodium (Rh), platinum (Pt), iridium (Ir), ruthenium (Ru), and copper (Cu); and

-n is 1, 2 or 3 ~~depending on the metal; under suitable conditions to cause the formation of a coordinate bond between $[M(H_20)_3(CO)_3]^{n+}$ and the tertiary amine nitrogen atom of the solid phase bound organic conjugate and thereby the release of the metal complexed agent thus formed from the support~~.

2. (Currently Amended) Process according to claim 1, wherein ~~the~~ L is a linker ~~is~~ selected from the group consisting of phenyl, vinyl, alkyl, allyl, aryl, and other non-aliphatic and aliphatic groups.

3. (Currently Amended) Process according to claim 2, wherein ~~the phenyl, vinyl, aryl or other non-aliphatic and aliphatic groups are~~L is substituted with an electron withdrawing group selected from OR, R, and $N(R)_2$, wherein R is an aliphatic or arylic group.

4. (Currently Amended) Process according to claims 1~~2~~, wherein ~~the linker~~L is as shown in formula II:



(II)

wherein X_1 is C or O, and each of X_2 is an electron withdrawing substituents ~~and preferably a $-OCH_3$ group~~.

5. (Currently Amended) Process according to claim 1, wherein at least one of R_1 and/~~or~~ R_2 ~~are~~ is selected from the group consisting of



$R3-NH_2$

wherein R3 is a tertiary amine, or an aliphatic chain containing 1, 2 or 3 carbons.

6. (Currently Amended) Process according to claim 1, wherein at least one of R_1 and R_2 ~~are~~ is an aliphatic or aromatic substituent~~, such as CH_3, C_2H_5 or $CH_2C_6H_5$~~.

7. (Currently Amended) Process according to claim 1, ~~wherein M is selected from the group consisting of Tc, Re, Ru, Rh, Ir, Cu and Pt~~further comprising forming a coordinate bond between $[M(H_20)_3(CO)_3]^{n+}$ and a tertiary amine nitrogen atom of the solid phase bound organic conjugate, and releasing a metal complexed agent thus formed.

8. (Currently Amended) Process ~~as claimed in~~according to claim ~~7~~1, wherein ~~the metal~~M is selected from the group consisting of ^{99m}Tc, ^{186}Re and ^{188}Re.

9. (Currently Amended) Process according to claim 1, wherein the biologically active molecule is selected from the group consisting of amino acids~~;~~, steroids~~;~~, peptides~~;~~, proteins, ~~in particular structural proteins, enzymes or antibodies;~~ carbohydrates, ~~;~~polysaccharides, ~~and~~ oligosaccharides~~;~~, nucleosides~~;~~, nucleotides~~;~~, oligonucleotides, ~~and~~ polynucleotides~~;~~, lipids~~;~~, ~~peptides~~ and pharmaceutically active small molecules ~~such as central nervous system receptor binding compounds~~.

10. (Currently Amended) Process according to claim 1, wherein the solid phase support is a polyethylene glycol resin~~;~~ or a hybrid of polyethylene glycol and polystyrene~~, e. g. a polystyrene resin with polyethylene glycol spacers with a benzyl alcohol anchoring group~~.

11. (Cancelled).

12. (Currently Amended) Process according to claim 1, wherein the process is performed at a pH that is in the range of about 6.0-11.0~~, preferably in the range of about 7.5-9.5~~.

13. (Currently Amended) Process according to claim 1, wherein the process is performed at a temperature in the range of about 40-100 C~~, preferably in the range of about 70-82 C~~.

14. (Cancelled).

15. (Currently Amended) A solid phase bound organic conjugate represented by ~~the~~ formula (I)



(I)

wherein the sphere is a solid phase support;

C is a methylene group;

R_4 and R_5 are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond; and

each of R_1 and R_2 is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule~~L, C, R_1, R_2, R_4 and R_5 are as defined in claim 1~~.

16. (Currently Amended) A solid phase bound organic ~~molecule~~ conjugate according to claim 15, ~~characterized in that~~wherein the biologically active molecule is selected from the group consisting of amino acids~~;~~, steroids~~;~~, peptides~~;~~, proteins~~,~~ ~~in particular structural proteins, enzymes or antibodies;~~ carbohydrates~~;~~, polysaccharides, ~~and~~ oligosaccharides~~;~~, nucleosides, nucleotides, oligonucleotides, ~~and~~ polynucleotides~~;~~, lipids, ~~peptides~~ and pharmaceutically active small molecules ~~such as central nervous system receptor binding compounds~~.

17. (Currently Amended) A solid phase bound organic ~~molecule~~ conjugate according to claim 15, wherein the solid phase support is a polyethylene glycol resin~~,~~ or a hybrid of polyethylene glycol and polystyrene~~, e.g. a polystyrene resin with polyethylene glycol spacers with a benzyl alcohol anchoring group~~.

18-19. (Cancelled).

20. (Currently Amended) A kit for the preparation of a diagnostic or therapeutic pharmaceutical composition, the kit comprising:

-a container; and

~~with the~~ a molecule of formula (I),



(I)

wherein the sphere is a solid phase;

C is a methylene group;

R_4 and R_5 are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond; and

each of R_1 and R_2 is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule.

in which the reaction with a solution of $[M(H_20)_3(CO)_3]^{n+}$ can take place.

21. (Original) Kit as claimed in claim 20, wherein the container is a vessel or column.

22. (Currently Amended) Kit as claimed in claim 20, further comprising a solution of $[M(H_20)_3(CO)_3]^{n+}$, wherein M is a metal, and n is 1, 2 or 3.

23. (Currently Amended) Kit as claimed in claim 20, further comprising ~~the~~ reagents for ~~the~~ preparation of ~~the metal carbonyl~~ $[M(H_20)_3(CO)_3]^{n+}$, wherein M is a metal, and n is 1, 2 or 3.

24. (Original) Kit as claimed in claim 20, further comprising a facility for filtration.

Clean Listing of Claims:

1. (Currently Amended) Process for generating a metal complexed agent, comprising:

contacting a solid phase bound organic conjugate represented by formula (I) with $[M(H_20)_3(CO)_3]^{n+}$,



(I)

wherein:

the sphere is a solid phase support;

C is a methylene group;

R_4 and R_5 are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond; and

each of R_1 and R_2 is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule,

wherein M is selected from the group consisting of technetium (Tc), rhenium (Re), rhodium (Rh), platinum (Pt), iridium (Ir), ruthenium (Ru), and copper (Cu); and

n is 1, 2 or 3.

2. (Currently Amended) Process according to claim 1, wherein L is a linker selected from the group consisting of phenyl, vinyl, alkyl, allyl, aryl, and other non-aliphatic and aliphatic groups.

3. (Currently Amended) Process according to claim 2, wherein L is substituted with an electron withdrawing group selected from OR, R and $N(R)_2$, wherein R is an aliphatic or arylic group.

4. (Currently Amended) Process according to claim 1, wherein L is as shown in formula II:



(II)

wherein X_1 is C or O, and each of X_2 is an electron withdrawing substituent.

5. (Currently Amended) Process according to claim 1, wherein at least one of R_1 and R_2 is selected from the group consisting of





wherein R3 is a tertiary amine, or an aliphatic chain containing 1, 2 or 3 carbons.

6. (Currently Amended) Process according to claim 1, wherein at least one of R_1 and R_2 is an aliphatic or aromatic substituent.

7. (Currently Amended) Process according to claim 1, further comprising forming a coordinate bond between $[M(H_20)_3(CO)_3]^{n+}$ and a tertiary amine nitrogen atom of the solid phase bound organic conjugate, and releasing a metal complexed agent thus formed.

8. (Currently Amended) Process according to claim 1, wherein M is selected from the group consisting of ^{99m}Tc, ^{186}Re and ^{188}Re.

9. (Currently Amended) Process according to claim 1, wherein the biologically active molecule is selected from the group consisting of amino acids, steroids, peptides, proteins, carbohydrates, polysaccharides, oligosaccharides, nucleosides, nucleotides, oligonucleotides, polynucleotides, lipids, and pharmaceutically active small molecules.

10. (Currently Amended) Process according to claim 1, wherein the solid phase support is a polyethylene glycol resin or a hybrid of polyethylene glycol and polystyrene.

11. (Cancelled).

12. (Currently Amended) Process according to claim 1, wherein the process is performed at a pH that is in the range of about 6.0-11.0.

13. (Currently Amended) Process according to claim 1, wherein the process is performed at a temperature in the range of about 40-100 C.

14. (Cancelled).

15. (Currently Amended) A solid phase bound organic conjugate represented by formula (I)



(I)

wherein the sphere is a solid phase support;

C is a methylene group;

R_4 and R_5 are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond; and

each of R_1 and R_2 is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule.

16. (Currently Amended) A solid phase bound organic conjugate according to claim 15, wherein the biologically active molecule is selected from the group consisting of amino acids, steroids, peptides, proteins, carbohydrates, polysaccharides, oligosaccharides, nucleosides, nucleotides, oligonucleotides, polynucleotides, lipids, and pharmaceutically active small molecules.

17. (Currently Amended) A solid phase bound organic conjugate according to claim 15, wherein the solid phase support is a polyethylene glycol resin or a hybrid of polyethylene glycol and polystyrene.

18-19. (Cancelled).

20. (Currently Amended) A kit for the preparation of a diagnostic or therapeutic pharmaceutical composition, the kit comprising:

a container; and

a molecule of formula (I),



(I)

wherein the sphere is a solid phase;

C is a methylene group;

R_4 and R_5 are independently selected from the group consisting of H, aliphatic substituents, aromatic substituents, RO, RS and $(R)_2N$, wherein R is an aliphatic or arylic group;

L is a linker or a single bond; and

each of R_1 and R_2 is independently a metal coordinating group, a non-coordinating organic group, a metal coordinating group derivatized with a biologically active molecule, or a non-coordinating organic group derivatized with a biologically active molecule.

in which the reaction with a solution of $[M(H_20)_3(CO)_3]^{n+}$ can take place.

21. (Original) Kit as claimed in claim 20, wherein the container is a vessel or column.

22. (Currently Amended) Kit as claimed in claim 20, further comprising a solution of $[M(H_20)_3(CO)_3]^{n+}$, wherein M is a metal, and n is 1, 2 or 3.

23. (Currently Amended) Kit as claimed in claim 20, further comprising reagents for preparation of $[M(H_20)_3(CO)_3]^{n+}$, wherein M is a metal, and n is 1, 2 or 3.

24. (Original) Kit as claimed in claim 20, further comprising a facility for filtration.